Pursuant to the Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and amendments ....

Date: 12th August, 2026 Corporate Services Department, BSE Limited, Phiroze Jeejeebhoy Towers, 1st Floor, Dalal Street, Fort, Mumbai - 400001. Scrip Code: 540204 Subject: Outcome of the Board Meeting Dear Sir/Madam, Pursuant to the Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Wednesday, 12th August, 2026, which commenced at 1:00 PM, and concluded at 01:40 PM, Board, inter-alia, approved and taken on record the following: 1. Approved Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 along with Limited Review Report issued by the Statutory Auditors of the Company. A Copy of the same is enclosed herewith as Annexure - I Thanking you, For Eiko Lifesciences Limited Chintan Doshi Company Secretary and Compliance Officer Membership No: A 36190 Eiko LifeSciences Limited, CIN: L65993MH1977PLC258134 Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604 Mobile No.: +919082668855; Email id: investor.rela(cid:415)ons@eikolifesciences.com website: www.eikolifesciences.com Annexure - I P SV Jain & Associates Chartered Accountants Yashwant Shopping Centre, 126, Carter Rd No. 7, Chinchpada, Borivali East, Mumbai, Maharashtra 400066 INDIA Independent Auditor's Review Report on Standalone Unaudited Financial Results Quarter ended 30% June 2026 of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors Eiko Lifesciences Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results (‘the Statement') of Eiko Lifesciences Limited (The Company') for the Quarter ended 30" June 2026 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting” ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, includitnhge manner in which it is to be disclosed, or that it contains any material misstatement. For PSV JAIN & ASSOCIATES Chartered Accountants Firm Registration No.: 131505W CA Dularesh Kumar Jain Partner Place: Thane Membership No.: 137264 Date: 12" August 2026 UDIN: 26137264HYHEBL8488 EIKO LIFESCIENCES LIMITED (CIN: L65993MH1977PLC258134) STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30™ JUNE 2026 (INRinlakhs) Quarter Ended Year Ended '3:. Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) 1 Revenue from operations 1,417.81 1,590.35 745.23 4,212.68 Other income 68.34 45.44 55.37 212.93 Total revenue 1,486.15 1,635.79 800.60 4,425.61 2 Expenses Cost of Material consumed 1,324.50 1,587.27 460.05 3,728.41 Changes in inventories of finished stock and work-in-progress (40.96) (159.35) 196.38 131 Employee benefits expense 7.16 7.17 5.85 29.01 Depreciation and amortization expense 14.74 14.74 14.75 59.02 Finance Cost 4.06 3.82 1.82 16.29 Other expenses 36.21 32.81 30.97 120.28 Total expenses 1,345.71 1,486.46 709.82 3,954.31 3 Profit/(Loss) from ordinary activities hefore Exceptional ltems 140.45 14933 %077 7130 and Tax Exceptional ltems - - - - 4 Profit/(Loss) from ordinary activities before Tax 140.45 149.33 90.77 471.30 5 Taxexpense: (1) Current tax 32.65 34.72 19.93 104.93 (2) Deferred tax 1.36 221 1.62 8.25 6 Profit/(Loss) from ordinary activities after tax 106.44 112.39 69.22 358.11 7 Other Comprehensive Income (OCI) (et of taxes) - 8 Total Comprehensive Income 106.44 112.39 69.22 358.11 9 Paid up Equity Share Capital (Face Value of Rs. 10 each) 1,434.59 1,434.59 1,376.27 1,434.59 10 Other Equity 4,909.65 11 Earnings Per Share (EPS) (Not annualised) (1) Basic 0.74 0.80 0.50 2.60 (2) Diluted 0.62 0.74 0.50 2.54 NOTES 1. The Standalone Financial Results for the quarter ended 30" June 2026 were reviewed by the Audit Committee and recommended to the Board, which was thereafter approved by the Board of Directors of the Company at its meeting held on 12" August 2026. 2. The company has a single business segment, namely "Speciality & Fine Chemicals", therefore in the context of Ind AS 108, disclosure of segment information is not applicable. 3. Thefiguresfor the Quarter ended 31<*March 2026 are the balancing figures between audited figures in respect of the full financial year 2025-26 and the publisyehaer tdo date figures upto the third quarter of the financial year 2025-26. 4. Figures for the previous period have been regrouped/ reclassified wherever necessary to conform to current period's classification. For Eiko LifeSciences Limited Laxmikant Kabra Chairman Date: 12" August 2026 DIN: 00061346 Place: Thane P SV Jain & Associates Chartered Accountants Yashwant Shopping Centre, 126, Carter Rd No. 7, Chinchpada, Borivali East, Mumbai, Maharashtra 400066 INDIA d Financial Results for Quarter ended 30" June 2026 of the Independent Auditor's Review Report on Consolidated Unaudi Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). To the Board of Directors Eiko LifeSciences Limited 1. We have reviewed the accompanying statement of unaudited consolidated financial results (the Statement') of Eiko LifeSciences Limited (the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as 'the Group') and its associate for the quarter ended 30" June 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ( [Showing first 8,000 characters — download PDF for full document]